Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 3,229 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Terminated Not applicable Interventional Results available

The Effect of Irrisept for Irrigation of Skin and Soft Tissue Infections (Irrisept USF Study)

NCT01076049
View directory record Official record
Conditions
Skin and Soft Tissue Infections, Abscess
Interventions
Standard of Care (SoC), Irrisept Delivery System
Device
Lead sponsor
Irrimax Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 24, 2026, 10:34 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

NCT05314738
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
NXL Energy 1, NXL Energy 2, NXL Energy 3, Sham Treatment
Combination Product
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Dothan, Alabama • Teaneck, New Jersey • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 24, 2026, 10:34 AM EDT
Withdrawn Phase 4 Interventional

ABC Blocks for Cardiac Surgery

NCT05589363
View directory record Official record
Conditions
Pain
Interventions
ABC block with bupivacaine/liposomal bupivacaine, ABC block with saline
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Abaloparatide and Pelvic Fracture Healing

NCT04249232
View directory record Official record
Conditions
Fracture of Pelvis (Disorder)
Interventions
Abaloparatide 80 micrograms per Pen dose, Placebo prefilled injector pen
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
New York, New York • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

NCT02363738
View directory record Official record
Conditions
Bipolar Depression
Interventions
Infliximab, Saline
Drug · Other
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia

NCT02604433
View directory record Official record
Conditions
Erythrocyte Transfusion, Beta-Thalassemia
Interventions
Luspatercept, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 1 Interventional

Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita

NCT00716014
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
TD101, Normal saline (placebo)
Drug
Lead sponsor
Pachyonychia Congenita Project
Other
Eligibility
10 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Marketing Workplace Chronic Disease Prevention

NCT00452816
View directory record Official record
Conditions
Health Behavior, Chronic Disease
Interventions
Workplace Solutions Consulting approach, Delayed intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 20, 2009 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)

NCT04535947
View directory record Official record
Conditions
Dry Eye
Interventions
Vehicle, SDP-4 Ophthalmic Solution (1.0%)
Drug
Lead sponsor
Silk Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Garden Grove, California • Murrieta, California • Newport Beach, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants

NCT02153099
View directory record Official record
Conditions
Dose Finding Study
Interventions
TAK-058 (ENV8058), Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

NCT05938699
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
NCX 470, Placebo
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 24, 2026, 10:34 AM EDT
Terminated Phase 4 Interventional Results available

Does Topical Otic Drop Use at Time of Tympanostomy Tube Surgery Improve Outcomes When no Middle Ear Effusion is Present

NCT03655665
View directory record Official record
Conditions
Otitis Media
Interventions
Ofloxacin otic solution
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

NCT02257151
View directory record Official record
Conditions
Healthy Adult
Interventions
BMS-986142, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

NCT00549939
View directory record Official record
Conditions
Neurogenic Urinary Bladder
Interventions
Alfuzosin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 16 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 24, 2026, 10:34 AM EDT
Not listed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

NCT05205070
View directory record Official record
Conditions
Alopecia Areata
Interventions
Rosnilimab, Placebo
Biological
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Encinitas, California • Northridge, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 24, 2026, 10:34 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Family Dyad-focused Diabetes Self-Management Intervention for African American Adults

NCT05905575
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Family dyad diabetes intervention
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 90 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 24, 2026, 10:34 AM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration

NCT01601483
View directory record Official record
Conditions
Nonexudative Age Related Macular Degeneration
Interventions
MC-1101, MC-1101 Vehicle
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 24, 2026, 10:34 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

NCT02515669
View directory record Official record
Conditions
Muscular Dystrophy (DMD)
Interventions
RO7239361, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 10 Years · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

NCT03627494
View directory record Official record
Conditions
Muscular Dystrophies
Interventions
GSK3439171A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 3 Interventional

A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache

NCT00033839
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Civamide (Zucapsaicin)
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
26
States / cities
Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects

NCT02508753
View directory record Official record
Conditions
Healthy
Interventions
CXA-101/tazobactam, Moxifloxacin, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant Mucositis

NCT03400475
View directory record Official record
Conditions
Peri-implant Mucositis
Interventions
Simvastatin, Placebo
Drug · Other
Lead sponsor
Ahmed Mohamed Mahrous
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 24, 2026, 10:34 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach

NCT03772262
View directory record Official record
Conditions
Interaction Drug Food
Interventions
goldenseal, Metformin, Furosemide, Midazolam oral solution, Rosuvastatin Oral Tablet
Dietary Supplement · Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 24, 2026, 10:34 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Caffeine in the Second Stage of Labor in Low-risk Nulliparous Mothers at Term

NCT05906303
View directory record Official record
Conditions
Second Stage of Labor
Interventions
Caffeine and Sodium Benzoate Injection, Normal Saline
Drug
Lead sponsor
The Reading Hospital and Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 24, 2026, 10:34 AM EDT